Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
22:50 - 23:00 | Presenter: Yun Fan
- Abstract
This abstract is currently under embargo and will be released during the conference.
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-014 - Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Presenter: Caicun Zhou- Abstract
Loading... -
+
EP08.01-032 - Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-033 - ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.01-042 - NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Presenter: Ying Cheng- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Presenter: James Chih-Hsin Yang- Abstract
Loading... -
+
EP08.02-051 - High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-052 - Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Presenter: Yun Fan- Abstract
Loading... -
+
EP08.02-078 - Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Presenter: Ying Cheng- Abstract
Loading... -
+
EP08.02-092 - Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Presenter: Na Li- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- 08:30 - 10:20
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Plenary
- Track: N/A
- Moderators:Heather Wakelee, Eric Lim
-
+
PL03.09 - IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Presenter: ENRIQUETA FELIP- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
12:07 - 12:12 | Presenter: Yun Fan
- Abstract
Loading...
